Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: TRM003
MIFTS: 48

Tremor

Categories: Genetic diseases, Mental diseases, Muscle diseases, Neuronal diseases, Oral diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Tremor

About this section

MalaCards integrated aliases for Tremor:

Name: Tremor 53 29 6 42
Tremors 6

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Neuronal diseases Muscle diseases Oral diseases Mental diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

ICD10 32 R25.1
Sources

Summaries for Tremor

About this section
MedlinePlus : 42 What is a tremor? A tremor is a rhythmic shaking movement in one or more parts of your body. It is involuntary, meaning that you cannot control it. This shaking happens because of muscle contractions. A tremor is most often in your hands, but it could also affect your arms, head, vocal cords, trunk, and legs. It may come and go, or it may be constant. Tremor can happen on its own or be caused by another disorder. What are the types of tremor? There are several types of tremor, including Essential tremor, sometimes called benign essential tremor. This is the most common type. It usually affects your hands, but it can also affect your head, voice, tongue, legs, and trunk. Parkinsonian tremor, which is a common symptom in people who have Parkinson's disease. It is usually affects one or both hands when they are at rest, but it can affect the chin, lips, face, and legs. Dystonic tremor, which happens in people who have dystonia. Dystonia is a movement disorder in which you have involuntary muscle contractions. The contractions cause you to have twisting and repetitive movements. It can affect any muscle in the body. What causes tremor? Generally, tremor is caused by a problem in the deep parts of the brain that control movements. For most types, the cause is unknown. Some types are inherited and run in families. There can also be other causes, such as Neurologic disorders, including multiple sclerosis, Parkinson's disease, stroke, and traumatic brain injury Certain medicines, such as asthma medicines, amphetamines, caffeine, corticosteroids, and medicines used for certain psychiatric and neurological disorders Alcohol use disorder or alcohol withdrawal Mercury poisoning Hyperthyroidism (overactive thyroid) Liver or kidney failure Anxiety or panic Who is at risk for tremor? Anyone can get tremor, but it is most common in middle-aged and older adults. For certain types, having a family history raises your risk of getting it. What are the symptoms of tremor? Symptoms of tremor may include Rhythmic shaking in the hands, arms, head, legs, or torso Shaky voice Difficulty writing or drawing Problems holding and controlling utensils, such as a spoon How is tremor diagnosed? To make a diagnosis, your health care provider Will take your medical history Will do a physical exam, which includes checking Whether the tremor happens when the muscles are at rest or in action The location of the tremor How often you have the tremor and how strong it is Will do a neurological exam, including checking for Problems with balance Problems with speech Increased muscle stiffness May do blood or urine tests to look for the cause May do imaging tests to help figure out if the cause is damage in your brain May do tests which check your abilities to do daily tasks such as handwriting and holding a fork or cup May do an electromyogram. This is a test which measures involuntary muscle activity and how your muscles respond to nerve stimulation What are the treatments for tremor? There is no cure for most forms of tremor, but there are treatments to help manage symptoms. In some cases, the symptoms may be so mild that you do not need treatment. Finding the right treatment depends on getting the right diagnosis of the cause. Tremor caused by another medical condition may get better or go away when you treat that condition. If your tremor is caused by a certain medicine, stopping that medicine usually makes the tremor go away. Treatments for tremor where the cause is not found include Medicines. There are different medicines for the specific types of tremor. Another option is Botox injections, which can treat several different types. Surgery may be used for severe cases that do not get better with medicines. The most common type is deep brain stimulation (DBS). Physical, speech-language, and occupational therapy, which may help to control tremor and deal with the daily challenges caused by the tremor If you find that caffeine and other stimulants trigger your tremors, it may be helpful to cut them from your diet. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Tremor, also known as tremors, is related to tremor, hereditary essential, 1 and fragile x tremor/ataxia syndrome. An important gene associated with Tremor is C19orf12 (Chromosome 19 Open Reading Frame 12). The drugs Pregabalin and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, subthalamic nucleus and thalamus, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

NINDS : 53 Tremor is an unintentional, rhythmic, muscle movement involving to-and-fro movements of one or more parts of the body. Most tremors occur in the hands, although they can also affect the arms, head, face, voice, torso, and legs. Generally, tremor is caused by a problem in the deep parts of the brain that control movements.  Some forms of tremor are inherited and run in families, while others have no known cause. Sometimes tremor is a symptom of another neurological disorder or a side effect of certain drugs, but the most common form occurs in otherwise healthy people. Excessive alcohol consumption or alcohol withdrawal can kill certain nerve cells, resulting in tremor, especially in the hand. Other causes include an overactive thyroid and the use of certain drugs. Tremor may occur at any age but is most common in middle-aged and older adults. There are several types of tremor, one of the most common of which is essential tremor (sometimes called benign essential tremor). The hands are most often affected but the head, voice, tongue, legs, and trunk may also be involved. Head tremor may be seen as a "yes-yes" or "no-no" motion. Onset is most common after age 40, although symptoms can appear at any age. Parkinsonian tremor is caused by damage to structures within the brain that control movement. The tremor is classically seen as a "pill-rolling" action of the hands but may also affect the chin, face, lips, and legs. Dystonic tremor occurs in individuals of all ages who are affected by dystonia, a movement disorder which causes muscles to be over-active, resulting in abnormal postures or sustained, unwanted movements.

Wikipedia : 74 A tremor is an involuntary, somewhat rhythmic, muscle contraction and relaxation involving oscillations... more...

Sources

Related Diseases for Tremor

About this section

Diseases in the Tremor family:

Tremor, Hereditary Essential, 1 Tremor, Hereditary Essential, 2
Tremor, Hereditary Essential, 3 Tremor, Hereditary Essential, 4
Tremor, Hereditary Essential, 5 Tremor, Hereditary Essential, 6
Essential Tremor Rare Tremor Disorder

Diseases related to Tremor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 856)
# Related Disease Score Top Affiliating Genes
1 tremor, hereditary essential, 1 33.0 TENM4 FUS DRD3
2 fragile x tremor/ataxia syndrome 32.9 FRAXA FMR1
3 tremor, hereditary essential, 5 32.8 TENM4 DNAJC13
4 tremor, hereditary essential, 4 32.7 TENM4 FUS DNAJC13
5 essential tremor 32.6 TENM4 NOTCH2NLC LRRK2 GBA FUS FMR1
6 tremor, hereditary essential, 3 32.6 TENM4 FUS DRD3
7 tremor, hereditary essential, 2 32.6 TENM4 FUS ETM2 DRD3
8 parkinson disease 21 31.7 LRRK2 DNAJC13
9 parkinson disease, late-onset 31.6 LRRK2 LOC106627981 GBA FMR1 DRD3 DNAJC13
10 parkinson disease 1, autosomal dominant 31.5 LRRK2 GBA
11 movement disease 31.4 LRRK2 LOC106627981 GBA FUS FMR1 DRD3
12 parkinson disease 15, autosomal recessive early-onset 31.3 LRRK2 C19orf12
13 kufor-rakeb syndrome 31.3 LRRK2 GBA C19orf12
14 dementia, lewy body 31.3 LRRK2 LOC106627981 GBA FUS
15 supranuclear palsy, progressive, 1 31.0 LRRK2 GBA FUS
16 aceruloplasminemia 30.9 MT-ATP6 HARS1 C19orf12
17 fmr1 disorders 30.8 FRAXA FMR1
18 early-onset parkinson's disease 30.1 LRRK2 GBA C19orf12
19 dementia 29.9 MT-ATP6 LRRK2 LOC106627981 GBA FUS FMR1
20 peripheral nervous system disease 29.9 MT-ATP6 MPZ LRRK2 HARS1 FIG4
21 tooth disease 29.5 MT-ATP6 MPZ HARS1 FIG4
22 fragile x-associated tremor/ataxia syndrome 11.5
23 primary orthostatic tremor 11.4
24 myopathy, congenital, with tremor 11.4
25 tremor, hereditary essential, 6 11.4
26 epilepsy, familial adult myoclonic, 5 11.4
27 epilepsy, familial adult myoclonic, 3 11.4
28 epilepsy, familial adult myoclonic, 2 11.4
29 epilepsy, familial adult myoclonic, 1 11.3
30 leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism 11.3
31 neurodegeneration, childhood-onset, with ataxia, tremor, optic atrophy, and cognitive decline 11.3
32 epilepsy, familial adult myoclonic, 4 11.3
33 epilepsy, familial adult myoclonic, 6 11.3
34 epilepsy, familial adult myoclonic, 7 11.3
35 polr3-related leukodystrophy 11.3
36 mental retardation, x-linked, syndromic, cabezas type 11.2
37 myoclonic cerebellar dyssynergia 11.2
38 dystonia 11.2
39 mental retardation, autosomal recessive 48 11.1
40 leukoencephalopathy with dystonia and motor neuropathy 11.1
41 familial adult myoclonic epilepsy 11.1
42 parkinsonism 11.1
43 multiple system atrophy 1 11.0
44 tremor, nystagmus, and duodenal ulcer 11.0
45 tremor, hereditary essential, and idiopathic normal pressure hydrocephalus 11.0
46 hyperthyroidism 11.0
47 sensorineural hearing loss-early graying-essential tremor syndrome 11.0
48 leukodystrophy, hypomyelinating, 2 11.0
49 cerebellar degeneration 11.0
50 ataxia and polyneuropathy, adult-onset 11.0

Graphical network of the top 20 diseases related to Tremor:



Diseases related to Tremor
Sources

Symptoms & Phenotypes for Tremor

About this section

GenomeRNAi Phenotypes related to Tremor according to GeneCards Suite gene sharing:

26 (show all 19)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.62 GBA
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-118 9.62 GBA
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-132 9.62 DRD3
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-137 9.62 DRD3
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-151 9.62 GBA
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-159 9.62 DRD3
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 9.62 DRD3
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-175 9.62 HARS1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-29 9.62 HARS1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.62 GBA
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.62 HARS1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-51 9.62 DRD3 GBA
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-54 9.62 HARS1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.62 DRD3
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-67 9.62 DRD3
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-7 9.62 GBA
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.62 GBA
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-81 9.62 GBA
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-85 9.62 DRD3
Sources

Drugs & Therapeutics for Tremor

About this section

Drugs for Tremor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
2
Memantine Approved, Investigational Phase 4 19982-08-2 4054
3
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
4
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
5
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
7
Imidazole Experimental, Investigational Phase 4 288-32-4 795
8 Anticonvulsants Phase 4
9 Psychotropic Drugs Phase 4
10 Hormones Phase 4
11 Anti-Anxiety Agents Phase 4
12 Dopamine Agents Phase 4
13 Antiparkinson Agents Phase 4
14 Dopamine agonists Phase 4
15 Excitatory Amino Acid Antagonists Phase 4
16 Anti-Infective Agents Phase 4
17 Anti-Infective Agents, Local Phase 4
18 abobotulinumtoxinA Phase 4
19 Botulinum Toxins Phase 4
20 Botulinum Toxins, Type A Phase 4
21 Cholinergic Agents Phase 4
22 Immunosuppressive Agents Phase 4
23 Immunologic Factors Phase 4
24 Calcineurin Inhibitors Phase 4
25
Topiramate Approved Phase 3 97240-79-4 5284627
26
tannic acid Approved Phase 3 1401-55-4
27
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
28
Sodium oxybate Approved Phase 2, Phase 3 502-85-2 5360545
29
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
30
Ethanol Approved Phase 2, Phase 3 64-17-5 702
31 Hypoglycemic Agents Phase 3
32 Carbidopa, levodopa drug combination Phase 3
33 Anesthetics Phase 2, Phase 3
34 Anesthetics, Intravenous Phase 2, Phase 3
35 Anesthetics, General Phase 2, Phase 3
36 Antipsychotic Agents Phase 3
37
Levetiracetam Approved Phase 1, Phase 2 102767-28-2 441341
38
Dronabinol Approved, Illicit Phase 1, Phase 2 1972-08-3 16078
39 Strawberry Approved Phase 2
40
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
41
Propranolol Approved, Investigational Phase 2 525-66-6 4946
42
Levodopa Approved Phase 2 59-92-7 6047
43
Sage Approved Phase 2
44
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
45
Promethazine Approved, Investigational Phase 2 60-87-7 4927
46
Pregnanolone Investigational Phase 2 128-20-1 31402
47 Soy Bean Phase 2
48 Olive Phase 2
49 Epidiolex Phase 1, Phase 2
50 Pharmaceutical Solutions Phase 2

Interventional clinical trials:

(show top 50) (show all 256)
# Name Status NCT ID Phase Drugs
1 A Multi-site, Double-blind, Randomized, Placebo-controlled, Crossover Study of Pregabalin (Lyrica, PGB) in the Treatment of Essential Tremor Completed NCT00584376 Phase 4 Pregabalin;Placebo
2 Effects of Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity (Local Field Potentials) Measured Through Implanted Stimulators Completed NCT02256319 Phase 4 Dexmedetomidine;Propofol
3 Propranolol and Botulinum Toxin for Essential Vocal Tremor Completed NCT02111369 Phase 4 Propranolol
4 A Pilot Clinical Trial of Memantine for Essential Tremor Completed NCT00439699 Phase 4 Memantine
5 A 17 Week, Investigator-initiated, Single-center, Double-blind, Randomized, Placebo-controlled, Cross-over Trial of Pregabalin in Essential Tremor Completed NCT00646451 Phase 4 pregabalin;placebo capsules
6 Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response Completed NCT02495883 Phase 4 Propranolol
7 A Multicenter, Open-Label, Two-Arm Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management Completed NCT03103919 Phase 4 Rotigotine
8 Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Oculopalatal Tremor: a Controled Open-label Study Completed NCT02466191 Phase 4 Memantine;Gabapentin
9 RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR) Completed NCT00998660 Phase 4
10 A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients Recruiting NCT03461445 Phase 4 Envarsus;IR Tacrolimus
11 A Pilot Study of Stable Kidney Transplant Recipients Taking Tacrolimus With CNS Symptoms Switched to Envarsus Active, not recruiting NCT03270462 Phase 4 Envarsus XR
12 A Placebo-controlled, Double-blind, Randomized, Cross Over Pilot Study of the Efficacy and Tolerability of Abobotulinum Toxin A (Dysport) as a Treatment for Task-dependent Upper Limb Tremor Active, not recruiting NCT03136341 Phase 4 Abobotulinum toxin A
13 Atlas Predicted DBS Settings in Essential Tremor Suspended NCT02678429 Phase 4
14 A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in the Treatment of Essential Tremor Completed NCT00236496 Phase 3 topiramate
15 CSP #468 Phase II - A Comparison of Best Medical Therapy and Deep Brain Stimulation of Subthalamic Nucleus and Globus Pallidus for the Treatment of Parkinson's Disease, Phase II Completed NCT01076452 Phase 3
16 CSP #468 Phase I - A Comparison of Best Medical Therapy and Deep Brain Stimulation of Subthalamic Nucleus and Globus Pallidus for the Treatment of Parkinson's Disease Completed NCT00056563 Phase 3
17 Earlier Versus Later L-Dopa in Parkinson's Disease Completed NCT00004733 Phase 3 levodopa
18 Novel Therapies for Essential Tremor Completed NCT00018564 Phase 3 treatments for essential tremor
19 The Single Center, Phase III Clinical Trial to Evaluate the Efficacy and the Safety of [18F]FPCIT Positron Emission Tomography in Parkinson's Disease and Essential Tremor Patients Completed NCT00468078 Phase 3 F-18 FPCIT
20 Intravenous Dexmedetomidine for Treatment of Shivering During Cesarean Section Under Neuraxial Anesthesia: A Randomized Controlled Trial Completed NCT02384343 Phase 3 Dexmedetomidine;Normal saline
21 Diaphragmatic Breathing and Heart Rate Variability Training for Improving Hypertension in Fragile X Associated Tremor/Ataxia Completed NCT03816540 Phase 3
22 Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO) Completed NCT01438710 Phase 3 Prograf;LCP-Tacro
23 Double-Blind, Randomized, Controlled, Cross-over Comparison of Efficacy and Safety of Botulinum Toxin Type A in the Targeted Treatment of Disabling Tremor in Multiple Sclerosis Completed NCT01018485 Phase 3 Botulinum Toxin Type A
24 Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor by a Multi-center, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study Recruiting NCT02555982 Phase 3 BOTOX ® 200 Unités;Placebo
25 Bilateral Essential Tremor Treatment With Magnetic Resonance-guided Focused Ultrasound Recruiting NCT04501484 Phase 2, Phase 3
26 Central Mechanisms and Treatment Response of Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor Recruiting NCT03292458 Phase 2, Phase 3 Sodium Oxybate
27 A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy Controls Recruiting NCT04193527 Phase 3 DaTSCAN™ Ioflupane (123I) Injection
28 Bilateral Essential Tremor Treatment With Gamma Knife Not yet recruiting NCT04748640 Phase 2, Phase 3
29 Non-inferiority Study of the Molecular Imaging of Dopamine Transporters Using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to Distinguish Between Parkinson's Disease and Essential Tremor. Not yet recruiting NCT04265209 Phase 3 SPECT;PET
30 A 4 Week, Parallel-Design, Double-Blind, Placebo-Controlled Trial of Gabapentin in the Treatment of Neuroleptic-Induced Tremor: Clinical and Instrumental Ratings of Outcome. Terminated NCT00533455 Phase 3 Gabapentin
31 Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor: a Double-blind, Cross-over, Placebo-controlled Multicenter Study Withdrawn NCT01441284 Phase 3 pramipexole;placebo
32 Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation Withdrawn NCT00608231 Phase 2, Phase 3 Dexmedetomidine Hydrochloride Infusion;Normal Saline
33 An Evaluation of Effectiveness and Toxicity of CyberKnife Based Functional Radiosurgery for Parkinson Disease Patients Suffering From Tremor and Its Implementation in Poland Unknown status NCT02406105 Phase 2 CyberKnife
34 A Double-Blind, Cross-Over, Placebo-Controlled Efficacy and Tolerability Study of Perampanel and Essential Tremor Unknown status NCT02668146 Phase 2 Perampanel;Placebo
35 Transcranial Static Magnetic Field Stimulation (tSMS) in Essential Tremor Unknown status NCT03780426 Phase 2
36 Randomised Crossover Trial of Deep Brain Stimulation of Differential Posterior Subthalamic Area Regions in Parkinson's Disease and Tremor Unknown status NCT01945567 Phase 2
37 Effects of Octanoic Acid for Treatment of Essential Voice Tremor Completed NCT01864525 Phase 1, Phase 2 Octanoic acid;Inactive capsule
38 A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Safety, Tolerability and Proof of Concept Study of ST101 for Essential Tremor Completed NCT01332695 Phase 2 ST101;Placebo
39 Efficacy of Levetiracetam in Patients With Essential Tremor Completed NCT00620165 Phase 1, Phase 2 levetiracetam;placebo
40 Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response Completed NCT01961297 Phase 2 Sodium oxybate
41 Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor Completed NCT00102596 Phase 2 1-Octanol
42 Effect of Alcohol on Physiologic and Pathologic Tremors Completed NCT00001925 Phase 2 Alcohol
43 Novel Therapies for Essential Tremor - Zonisamide Pilot Study Completed NCT00223743 Phase 2 Zonisamide
44 Treatment Efficacy of 1-Octanol Compared to Placebo in Adults With Essential Tremor Completed NCT00080366 Phase 2 1-Octanol
45 Multiple-dose, Double-blind, Placebo-controlled, Crossover Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Sodium Oxybate (Xyrem) in Subjects With Moderate to Severe Essential Tremor Completed NCT00598078 Phase 2 Sodium Oxybate;Sodium Oxybate
46 A Double-Blind, Cross-Over, Placebo- Controlled Efficacy and Tolerability Study of Oral Cannabidiol (CBD) and Tetrahydrocannabinol (THC) for Essential Tremor (ET). Completed NCT03805750 Phase 1, Phase 2 CBD/THC;Placebo oral capsule
47 A Randomized, Double Blind, Placebo-Controlled, Crossover, Proof of Concept Study to Evaluate the Effectiveness and Safety of Carisbamate in the Treatment of Essential Tremor Completed NCT00524056 Phase 2 Carisbamate;Placebo
48 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Essential Tremor Completed NCT03101241 Phase 2 CX-8998;Placebo
49 A Double-blind, Placebo-controlled, Two-Period Crossover Proof-of-Concept Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-547 Injection in the Treatment of Patients With Essential Tremor Completed NCT02277106 Phase 2 SAGE-547;Placebo
50 Double-Blind, Placebo Controlled Pilot-Study of Octanoic Acid in Essential Tremor Completed NCT00848172 Phase 1, Phase 2 Octanoic Acid;Placebo

Search NIH Clinical Center for Tremor

Sources

Genetic Tests for Tremor

About this section

Genetic tests related to Tremor:

# Genetic test Affiliating Genes
1 Tremor 29
Sources

Anatomical Context for Tremor

About this section

MalaCards organs/tissues related to Tremor:

40
Brain, Subthalamic Nucleus, Thalamus, Cortex, Cerebellum, Tongue, Eye
Sources

Publications for Tremor

About this section

Articles related to Tremor:

(show top 50) (show all 22878)
# Title Authors PMID Year
1
Clinical Reasoning: A 24-year-old man with head tremor and decreased ceruloplasmin level. 42 61
32753443 2020
2
Dopamine-responsive and dopamine-resistant resting tremor in Parkinson disease. 61 42
32651292 2020
3
Yoga Breathing Exercises (Pranayama) Decrease Hand Microtremor in Young Microsurgeons: Toward a New Paradigm in Surgery. 42
32858659 2020
4
Efficacy of short-term multidisciplinary intensive rehabilitation in patients with different Parkinson's disease motor subtypes: a prospective pilot study with 3-month follow-up. 61
33318414 2021
5
Integrative Analysis of Gene Expression and Regulatory Network Interaction Data Reveals the Protein Kinase C Family of Serine/Threonine Receptors as a Significant Druggable Target for Parkinson's Disease. 61
32728898 2021
6
The development of an implantable deep brain stimulation device with simultaneous chronic electrophysiological recording and stimulation in humans. 61
33395569 2021
7
Predictors of Long-Term Outcome of Subthalamic Stimulation in Parkinson Disease. 61
33349939 2021
8
Combination targeting of subthalamic nucleus and ventral intermediate thalamic nucleus with a single trajectory in deep brain stimulation for tremor-dominant Parkinson's disease. 61
33581797 2021
9
Probabilistic Mapping of Deep Brain Stimulation: Insights from 15 Years of Therapy. 61
33252146 2021
10
Robust Dopaminergic Differentiation and Enhanced LPS-Induced Neuroinflammatory Response in Serum-Deprived Human SH-SY5Y Cells: Implication for Parkinson's Disease. 61
32789724 2021
11
Holmes tremor and palatal tremor in hypertrophic olivary degeneration: involvement of brainstem. 61
32851537 2021
12
What's down there? The structures, materials and environment of deep-seated slow slip and tremor. 61
33517877 2021
13
Clinical features associated with drooling in Parkinson's disease. 61
33443673 2021
14
Subacute thyroiditis in a patient infected with SARS-COV-2: an endocrine complication linked to the COVID-19 pandemic. 61
32676935 2021
15
Diagnostic approach to paediatric movement disorders: a clinical practice guide. 61
33150968 2021
16
Medial-tonsillar telovelar approach for resection of a superior medullary velum cerebral cavernous malformation: anatomical and tractography study of the surgical approach and functional implications. 61
32524247 2021
17
Transcranial magnetic resonance-guided focused ultrasound thalamotomy as a safe treatment option in multiple sclerosis patients with essential tremor. 61
33094429 2021
18
Management of Parkinson's disease and other movement disorders in women of childbearing age: Part 2. 61
32980194 2021
19
Dravet syndrome with parkinsonian symptoms and intact dopaminergic neurons: A case report. 61
33199159 2021
20
Cutaneomeningospinal Angiomatosis (Cobb Syndrome) in a Young Patient. 61
33602108 2021
21
Robotic Surgery for Male Infertility. 61
33218587 2021
22
Technology of deep brain stimulation: current status and future directions. 61
33244188 2021
23
Heterogeneous Nuclear Ribonucleoproteins: Implications in Neurological Diseases. 61
33000450 2021
24
Genetic characterization of a cohort with familial parkinsonism and cognitive-behavioral syndrome: A Next Generation Sequencing study. 61
33601107 2021
25
Repeat RNA expansion disorders of the nervous system: post-transcriptional mechanisms and therapeutic strategies. 61
33172304 2021
26
Refractory Syncope and Pre-syncope Associated with Atlanto-axial Instability: Preliminary Evidence of Improvement Following Surgical Stabilization. 61
33540088 2021
27
Robotic rectal cancer surgery with single side-docking technique: experience of a tertiary care university hospital. 61
32385797 2021
28
Neuropharmacological potentials of β-carboline alkaloids for neuropsychiatric disorders. 61
33359647 2021
29
Trends in safety and cost of deep brain stimulation for treatment of movement disorders in the United States: 2002-2014. 61
32476485 2021
30
A wearable tool for continuous monitoring of movement disorders: clinical assessment and comparison with tremor scores. 61
33594538 2021
31
Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson's disease heterogeneity. 61
33607526 2021
32
Closed-Loop Deep Brain Stimulation for Essential Tremor Based on Thalamic Local Field Potentials. 61
33547859 2021
33
Magnetic resonance-guided focused ultrasound for Parkinson's disease since ExAblate, 2016-2019: a systematic review. 61
33389248 2021
34
Comprehensive Analysis of Synonymous Codon Usage Bias for Complete Genomes and E2 Gene of Atypical Porcine Pestivirus. 61
33538926 2021
35
Long term follow-up in advanced Parkinson's disease treated with DBS of the subthalamic nucleus. 61
33598766 2021
36
[Robot-assisted Mediastinal Mass Resection]. 61
32767302 2021
37
Ambulatory surface electromyography with accelerometry for evaluating daily motor fluctuations in Parkinson's disease. 61
33450567 2021
38
Striatal dopamine transporter availability and individual clinical course within the 1-year follow-up of deep brain stimulation of the subthalamic nucleus in patients with Parkinson's disease. 61
33607613 2021
39
Objective and automated assessment of surgical technical skills with IoT systems: A systematic literature review. 61
33581827 2021
40
Pre-clinical evaluation of a novel robotic system for transoral robotic surgery. 61
33590692 2021
41
Accelerometer data collected with a minimum set of wearable sensors from subjects with Parkinson's disease. 61
33547309 2021
42
Mobile health technology to improve emergent frailty after lung transplantation. 61
33527520 2021
43
Abnormal cortico-basal ganglia neurotransmission in a mouse model of l-DOPA-induced dyskinesia. 61
33563724 2021
44
Safety and efficacy of magnetic resonance imaging-guided focused ultrasound neurosurgery for Parkinson's disease: a systematic review. 61
31814058 2021
45
Characterization of Retinal Microvascular and Choroidal Structural Changes in Parkinson Disease. 61
33355613 2021
46
Substantia nigra neuromelanin magnetic resonance imaging in patients with different subtypes of Parkinson disease. 61
33559725 2021
47
[18F]PR04.MZ PET/CT Imaging for Evaluation of Nigrostriatal Neuron Integrity in Patients With Parkinson Disease. 61
33323728 2021
48
Neurotoxic effects in zebrafish embryos by valproic acid and nine of its analogues: the fish-mouse connection? 61
33111190 2021
49
Peripheral electrical stimulation to reduce pathological tremor: a review. 61
33588841 2021
50
Toxic milk mice models of Wilson's disease. 61
33590415 2021
Sources

Variations for Tremor

About this section

ClinVar genetic disease variations for Tremor:

6 (show all 18)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 NUS1 NC_000006.11:g.(117961791_117961792)_(118280043_118280044)del Deletion Pathogenic 180225 6:117961791-118280044 6:117640628-117958881
2 NUS1 NC_000006.11:g.(117971549_117971550)_(118218719_118218720)del Deletion Pathogenic 180226 6:117971549-118218720 6:117650386-117897557
3 GPRC6A NC_000006.11:g.(116681080_116735056)_(119687719_119775014)del Deletion Pathogenic 180227 6:116681080-119775014
4 C19orf12 NM_001031726.3(C19orf12):c.424A>G (p.Lys142Glu) SNV Pathogenic 31158 rs146170087 19:30193654-30193654 19:29702747-29702747
5 HARS1 NM_002109.6(HARS1):c.616G>T (p.Asp206Tyr) SNV Pathogenic 804285 rs1131040 5:140057507-140057507 5:140677922-140677922
6 HARS1 NM_002109.6(HARS1):c.730delG Deletion Pathogenic 804286 rs1581505917 5:140057005-140057005 5:140677420-140677420
7 C19orf12 NM_001031726.3(C19orf12):c.205G>A (p.Gly69Arg) SNV Pathogenic 31157 rs515726205 19:30193873-30193873 19:29702966-29702966
8 LOC106627981 NM_000157.4(GBA):c.1093G>A (p.Glu365Lys) SNV risk factor 199044 rs2230288 1:155206167-155206167 1:155236376-155236376
9 TMEM67 NM_153704.6(TMEM67):c.1843T>C (p.Cys615Arg) SNV Likely pathogenic 1383 rs201893408 8:94808198-94808198 8:93795970-93795970
10 FIG4 NM_014845.5(FIG4):c.904G>A (p.Glu302Lys) SNV Likely pathogenic 156015 rs587777714 6:110064340-110064340 6:109743137-109743137
11 MPZ NM_000530.8(MPZ):c.699T>G (p.Ser233Arg) SNV Likely pathogenic 374017 rs1057518839 1:161275714-161275714 1:161305924-161305924
12 TMEM67 NM_153704.6(TMEM67):c.1321C>T (p.Arg441Cys) SNV Likely pathogenic 217725 rs752362727 8:94798483-94798483 8:93786255-93786255
13 MT-ATP6 NC_012920.1:m.9032T>C SNV Likely pathogenic 693061 rs1603221994 MT:9032-9032 MT:9032-9032
14 TBC1D24 NM_001199107.2(TBC1D24):c.920A>G (p.Asn307Ser) SNV Uncertain significance 583333 rs761934676 16:2547069-2547069 16:2497068-2497068
15 GLI2 NM_001374353.1(GLI2):c.2593A>T (p.Thr865Ser) SNV Uncertain significance 523482 rs1332140763 2:121746134-121746134 2:120988558-120988558
16 CACNA1H NM_021098.3(CACNA1H):c.6884C>T (p.Ser2295Phe) SNV Uncertain significance 523531 rs772718469 16:1270816-1270816 16:1220816-1220816
17 ADGRV1 NM_032119.4(ADGRV1):c.5188A>T (p.Ile1730Phe) SNV Uncertain significance 523543 rs1554079046 5:89971137-89971137 5:90675320-90675320
18 SYNE1 NM_182961.4(SYNE1):c.25015G>T (p.Gly8339Cys) SNV Uncertain significance 983391 6:152464862-152464862 6:152143727-152143727

Copy number variations for Tremor from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 247217 9 129375646 129461836 Deletion NIBAN2 Tremor
2 247222 9 129375646 129461836 Deletion STXBP1 Tremor
Sources

Expression for Tremor

About this section
Search GEO for disease gene expression data for Tremor.
Sources

Pathways for Tremor

About this section
Sources

GO Terms for Tremor

About this section

Biological processes related to Tremor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 determination of adult lifespan GO:0008340 9.32 LRRK2 GBA
2 negative regulation of voltage-gated calcium channel activity GO:1901386 9.26 FMR1 DRD3
3 autophagy GO:0006914 9.26 LRRK2 GBA DRD3 C19orf12
4 regulation of locomotion GO:0040012 9.16 LRRK2 DRD3
5 positive regulation of dopamine receptor signaling pathway GO:0060161 8.62 LRRK2 DRD3
Sources

Sources for Tremor

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....